Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 2023

						
U.S. APPLICATION NO.			FIRST NAMED APP	PLICANT		ATTY. DOCKET NO.
09/86919	8	C	ORDON			JAB-1463
,					INTERNATIONAL	APPLICATION NO.
PHILIP S JOHNSO	N			ł	PCT/US	99/30503
JOHNSON & JOHN		31 A 3 A				
ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933 7003					I.A. FILING DATE	PRIORITY DATE
	4 110 00000	, 000		1	21 DEC 99	22 DEC 98
No.		icaia anori		1 N N N A S 1	DATE MAILED:	20 SEP 2001
NOTIFICATIO						N THE UNITED
1		DESIGNATI		•	•	Fan down sale
1. The following item Office as		office (37 CFR 1.				Tagemark
<u></u> '	National Fe			Small Entity Sta		
Copy of the international application. Translation of the international a					o English.	
Oath or D	eclaration of	nventors(s).	Translation of	of Article 19 ame	ndments into En	glish.
Copy of A	rticle 19 ame	ndments.	Other:			
Priority D						
		ninary Examination				
[] I ranslatio	n of Annexes	to the Internation	a Preminary E	cammation Repor	n mio English.	
2. Applicant has rethe indicated items in prior to 20 or 30 month U.S. Basic	aragraph 3 boas from the p	clow. The Basic li iority date to avoi	National Fee and d abandonment.		nternational appl	
3. The following items	MUST be f	rnished within th	e period set forth	below in order	to complete the r	equirements for
acceptance under 35 U		-Marker land Park		a far will be as		.4
\Box	-	plication into Eng opriate 20 or 30 r		-	uirea ii subimite	:U
The	current transi	ation is defective	or the reasons in	dicated on the at	tached Notice of	Defective
	slation.					
L		oviding the transl				an the
c. Oath or	declaration of	30 months from the firm the firm the fiventors, in the firm of the	compliance with	37 CFR 1.497(a) and (b), prope	
	aarge will be	required if submit				
4		or declaration does		a 37 CFR 1.497(a) and (b) for the	reasons
		tached PCT/DO/ling the oath or de		an the appropriat	e 20 or 30 monti	is from the
		CFR 1.492(e)).	.•.			
 Additional claim fe claim fee, are required due (37 CFR 1.492(g)) 	. Applicant r	nust submit the ac				i multiple dependent for which fees are
5. Applicant has no			ice listing pursua	nt to 37 CFR 1.8	321-1.825. See	attached
PCT/DO/EO/920.	•					
ALL OF THE ITEMS MONTHS FROM TH THE PRIORITY DA' RESPOND WILL RE	E DATE OF TE FOR TH	THIS NOTICE E APPLICATION	OR BY 22 OR : N, WHICHEVE	32 MONTHS (w	here 37 CFR 1.	495 applies) FROM
The time period set about 1.136(a).	ove may be e	stended by filing a	petition and fee	for extension of	time under the p	rovisions of 37 CFR
6. If box 3a or 3c is c Annexes will be cancel 7. The Article 19 a or 30 (37 CFR 1.495(c	lled. A proce mendments a	ssing fee will be i re cancelled since	equired if submit a translation was	tted later than 20	or 30 months fro	om the priority date.
Applicant is reminded address given in the he	that any com	nunication to the lude the U.S. app	United States Pat lication no. show	ent and Tradema n above. (37 CF	rk Office must b R 1.5)	e mailed to the
,	A copy of	this notice N	IUST be ret	urned with t	this response	<i>e</i> .
Enclosed: PCT/Do		Notic	e of Defective T	ranslation	-	0.11
☐ PTO-87		PCT/	DO/EO/920	Dehorah	D Williams	77.1
FORM PCT/DO/FO/9	205 (March 2)	2017	;	Telephone: 703	D. Williams	<u>///</u> //

Commissioner for Patems, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY, DOCKET NO.	
09/869198	GORDON		JAB-1463	
	_	INTERNATIONAL APPLICATION NO.		
PHILIP S JOHNSON JOHNSON & JOHNSON		PCT/US99/30503		
ONE JOHNSON & JOHNSON PLA		I.A. FILING DATE	PRIORITY DATE	
NEW BRUNSWICK, NJ 08933 700	J3	21 DEC 99	22 DEC 98	
	}		- A CED 2001	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
'disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report.
substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:
APPLICANT MUST PROVIDE:
An initial or substitute computer readable form (CRF) of the "Sequence Listing."
An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as
amendment directing its entry into the specification.
A statement that the contents of the paper or compact disc and the computer readable form
are the same and, where applicable, include no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:
(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.
· · · · · · · · · · · · · · · · · · ·
Deborah D. Williams
Debotati B. Williams ():100

Telephone: 703-305-3744

FORM PCT/DO/EO/920 (March 2001)